RU2013140685A - ВАРИАНТЫ Fc, СПОСОБЫ ИХ ПОЛУЧЕНИЯ - Google Patents
ВАРИАНТЫ Fc, СПОСОБЫ ИХ ПОЛУЧЕНИЯ Download PDFInfo
- Publication number
- RU2013140685A RU2013140685A RU2013140685/10A RU2013140685A RU2013140685A RU 2013140685 A RU2013140685 A RU 2013140685A RU 2013140685/10 A RU2013140685/10 A RU 2013140685/10A RU 2013140685 A RU2013140685 A RU 2013140685A RU 2013140685 A RU2013140685 A RU 2013140685A
- Authority
- RU
- Russia
- Prior art keywords
- variant
- polypeptide
- modified igg
- heteromultimeric protein
- antibody
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 5
- 102000004169 proteins and genes Human genes 0.000 claims abstract 31
- 108090000623 proteins and genes Proteins 0.000 claims abstract 31
- 229920001184 polypeptide Polymers 0.000 claims abstract 25
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 25
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 25
- 150000001413 amino acids Chemical class 0.000 claims abstract 9
- 238000012986 modification Methods 0.000 claims abstract 8
- 230000004048 modification Effects 0.000 claims abstract 8
- 238000006467 substitution reaction Methods 0.000 claims abstract 7
- 230000015572 biosynthetic process Effects 0.000 claims abstract 5
- 235000018102 proteins Nutrition 0.000 claims 25
- 125000000539 amino acid group Chemical group 0.000 claims 8
- 230000035772 mutation Effects 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 6
- 235000001014 amino acid Nutrition 0.000 claims 5
- 238000005734 heterodimerization reaction Methods 0.000 claims 4
- 239000013604 expression vector Substances 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
- 230000013011 mating Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physics & Mathematics (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161439750P | 2011-02-04 | 2011-02-04 | |
| US61/439,750 | 2011-02-04 | ||
| PCT/US2012/023749 WO2012106587A1 (en) | 2011-02-04 | 2012-02-03 | Fc VARIANTS AND METHODS FOR THEIR PRODUCTION |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018108836A Division RU2018108836A (ru) | 2011-02-04 | 2012-02-03 | ВАРИАНТЫ Fc И СПОСОБЫ ИХ ПОЛУЧЕНИЯ |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013140685A true RU2013140685A (ru) | 2015-03-10 |
Family
ID=45607400
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018108836A RU2018108836A (ru) | 2011-02-04 | 2012-02-03 | ВАРИАНТЫ Fc И СПОСОБЫ ИХ ПОЛУЧЕНИЯ |
| RU2013140685/10A RU2013140685A (ru) | 2011-02-04 | 2012-02-03 | ВАРИАНТЫ Fc, СПОСОБЫ ИХ ПОЛУЧЕНИЯ |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018108836A RU2018108836A (ru) | 2011-02-04 | 2012-02-03 | ВАРИАНТЫ Fc И СПОСОБЫ ИХ ПОЛУЧЕНИЯ |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP2670776B1 (enExample) |
| JP (2) | JP6161540B2 (enExample) |
| KR (1) | KR101913448B1 (enExample) |
| CN (1) | CN103649117B (enExample) |
| AR (2) | AR085138A1 (enExample) |
| BR (1) | BR112013019499B1 (enExample) |
| CA (1) | CA2825064C (enExample) |
| MX (1) | MX355255B (enExample) |
| RU (2) | RU2018108836A (enExample) |
| WO (1) | WO2012106587A1 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| EP3296321B1 (en) | 2010-12-20 | 2020-07-15 | F. Hoffmann-La Roche AG | Anti-mesothelin antibodies and immunoconjugates |
| US10689447B2 (en) | 2011-02-04 | 2020-06-23 | Genentech, Inc. | Fc variants and methods for their production |
| SG10201805291TA (en) * | 2011-10-27 | 2018-08-30 | Genmab As | Production of heterodimeric proteins |
| AR090549A1 (es) | 2012-03-30 | 2014-11-19 | Genentech Inc | Anticuerpos anti-lgr5 e inmunoconjugados |
| SG11201407106XA (en) | 2012-05-01 | 2014-11-27 | Genentech Inc | Anti-pmel17 antibodies and immunoconjugates |
| PL2968520T3 (pl) * | 2013-03-14 | 2022-01-03 | Macrogenics, Inc. | Dwuspecyficzne cząsteczki, które są immunoreaktywne wobec immunologicznych komórek efektorowych wykazujących ekspresję receptora aktywującego |
| CN104211814A (zh) * | 2013-05-29 | 2014-12-17 | 三星电子株式会社 | 用于消耗靶膜蛋白的组合物 |
| KR102190220B1 (ko) * | 2013-05-29 | 2020-12-14 | 삼성전자주식회사 | 타겟 특이적 세포막 단백질 제거용 조성물 |
| HK1218124A1 (zh) | 2013-09-17 | 2017-02-03 | 豪夫迈．罗氏有限公司 | 使用抗lgr5抗体的方法 |
| US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| KR102480433B1 (ko) * | 2014-02-07 | 2022-12-21 | 맥마스터 유니버시티 | 3기능성 t 세포-항원 커플러 및 이의 제조 방법 및 용도 |
| LT3116909T (lt) | 2014-03-14 | 2020-02-10 | Novartis Ag | Antikūno molekulės prieš lag-3 ir jų panaudojimas |
| MX2016014409A (es) | 2014-05-06 | 2017-01-20 | Genentech Inc | Produccion de proteinas heteromultimericas usando celulas de mamifero. |
| KR102259232B1 (ko) * | 2014-08-25 | 2021-05-31 | 삼성전자주식회사 | 항 c-Met/항 Ang2 이중 특이 항체 |
| SG11201701623UA (en) | 2014-09-12 | 2017-03-30 | Genentech Inc | Anti-her2 antibodies and immunoconjugates |
| BR112017003236A2 (pt) | 2014-09-12 | 2017-11-28 | Genentech Inc | anticorpos elaborados com cisteína, conjugados de droga e anticorpos, método de preparação de conjugado de droga e anticorpo e composição farmacêutica |
| BR112017004826A2 (pt) | 2014-09-13 | 2017-12-12 | Novartis Ag | terapias de combinação de inibidores de alk |
| KR20170055521A (ko) | 2014-09-17 | 2017-05-19 | 제넨테크, 인크. | 항-her2 항체를 포함하는 면역콘주게이트 |
| SG11201702544WA (en) | 2014-09-29 | 2017-04-27 | Univ Duke | Bispecific molecules comprising an hiv-1 envelope targeting arm |
| MA43345A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation |
| TW201730211A (zh) | 2015-10-30 | 2017-09-01 | 建南德克公司 | 抗因子d抗體及結合物 |
| EP4671281A2 (en) | 2015-11-08 | 2025-12-31 | F. Hoffmann-La Roche AG | MULTISPECIFIC ANTIBODY SCREENING METHODS |
| CN118436801A (zh) | 2016-05-20 | 2024-08-06 | 豪夫迈·罗氏有限公司 | Protac抗体缀合物及其使用方法 |
| EP3465221B1 (en) | 2016-05-27 | 2020-07-22 | H. Hoffnabb-La Roche Ag | Bioanalytical method for the characterization of site-specific antibody-drug conjugates |
| JP7050770B2 (ja) | 2016-10-05 | 2022-04-08 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 抗体薬物コンジュゲートの調製方法 |
| WO2019071358A1 (en) | 2017-10-12 | 2019-04-18 | Mcmaster University | Y182T MUTATION T CELL ANTIGEN COUPLEUR AND METHODS AND USES THEREOF |
| KR102209108B1 (ko) | 2018-03-27 | 2021-01-28 | 국립암센터 | Oct4 기능 저해용 펩티드를 포함하는 줄기세포성 억제용 조성물 |
| US10640562B2 (en) | 2018-07-17 | 2020-05-05 | Mcmaster University | T cell-antigen coupler with various construct optimizations |
| US11110123B2 (en) | 2018-07-17 | 2021-09-07 | Triumvira Immunologics Usa, Inc. | T cell-antigen coupler with various construct optimizations |
| GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
| WO2020086858A1 (en) | 2018-10-24 | 2020-04-30 | Genentech, Inc. | Conjugated chemical inducers of degradation and methods of use |
| CN113227119A (zh) | 2018-12-10 | 2021-08-06 | 基因泰克公司 | 用于与含Fc的蛋白质进行位点特异性缀合的光交联肽 |
| GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
| CA3138576A1 (en) * | 2019-05-16 | 2020-11-19 | Trustees Of Boston University | Regulated synthetic gene expression systems |
| CN114981297A (zh) | 2019-12-23 | 2022-08-30 | 戴纳立制药公司 | 颗粒蛋白前体变体 |
| IL299860A (en) | 2020-07-21 | 2023-03-01 | Genentech Inc | Antibody-conjugated chemical factors for the discharge of BRM and their methods |
| GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
| JP2024509695A (ja) | 2021-02-03 | 2024-03-05 | ジェネンテック， インコーポレイテッド | 多重特異性結合タンパク質分解プラットフォームおよび使用方法 |
| WO2022197877A1 (en) | 2021-03-19 | 2022-09-22 | Genentech, Inc. | Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents |
| CA3173810A1 (en) | 2021-06-01 | 2022-12-01 | Andreas Bader | Claudin 18.2 t cell-antigen couplers and uses thereof |
| US20250136699A1 (en) * | 2021-08-13 | 2025-05-01 | Jiangsu Biojetay Biotechnology Co., Ltd. | Antibodies specifically recognizing fcrn and uses thereof |
| WO2024211846A1 (en) * | 2023-04-05 | 2024-10-10 | The Trustees Of Columbia University In The City Of New York | METHODS TO TREAT CANCER AND TO PREVENT IMMUNE-RELATED ADVERSE EVENTS (irAEs) OF CANCER IMMUNOTHERAPIES USING ANTI-IL-25 ANTIBODY |
| AU2024257248A1 (en) | 2023-04-17 | 2025-11-06 | Peak Bio, Inc. | Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates |
Family Cites Families (113)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
| IL47062A (en) | 1975-04-10 | 1979-07-25 | Yeda Res & Dev | Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde |
| US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
| US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
| US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
| JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
| JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
| US4665077A (en) | 1979-03-19 | 1987-05-12 | The Upjohn Company | Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds |
| JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
| JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
| JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
| JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
| EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
| WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
| US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
| US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
| JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| SE8505922D0 (sv) | 1985-12-13 | 1985-12-13 | Kabigen Ab | Construction of an igg binding protein to facilitate downstream processing using protein engineering |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
| US5053394A (en) | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
| IL85746A (en) | 1988-03-15 | 1994-05-30 | Yeda Res & Dev | Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases |
| FI891226L (fi) | 1988-04-28 | 1989-10-29 | Univ Leland Stanford Junior | Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom. |
| EP0435911B1 (en) | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| WO1990008187A1 (en) | 1989-01-19 | 1990-07-26 | Dana Farber Cancer Institute | Soluble two domain cd2 protein |
| ES2062519T5 (es) | 1989-03-21 | 2003-07-16 | Immune Response Corp Inc | Vacunacion y metodos contra enfermedades originadas a partir de respuestas patogenicas mediante poblaciones especificas de linfocitos t. |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| EP0552142B2 (en) | 1989-07-19 | 2003-12-17 | Corporation Connetics | T cell receptor peptides as therapeutics for autoimmune and malignant disease |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| ES2085983T3 (es) | 1989-12-20 | 1996-06-16 | Schering Corp | Antagonistas de anticuerpos de la interleuquina-4 humana. |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| US5264365A (en) | 1990-11-09 | 1993-11-23 | Board Of Regents, The University Of Texas System | Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides |
| US5508192A (en) | 1990-11-09 | 1996-04-16 | Board Of Regents, The University Of Texas System | Bacterial host strains for producing proteolytically sensitive polypeptides |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
| US5362852A (en) | 1991-09-27 | 1994-11-08 | Pfizer Inc. | Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties |
| EP1136556B1 (en) | 1991-11-25 | 2005-06-08 | Enzon, Inc. | Method of producing multivalent antigen-binding proteins |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| EP1005870B1 (en) | 1992-11-13 | 2009-01-21 | Biogen Idec Inc. | Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
| CZ292061B6 (cs) | 1994-03-17 | 2003-07-16 | Merck Patent Gmbh | Jednořetězcové fragmenty protilátek a protilátky proti receptoru epidermálního růstového faktoru, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5639635A (en) | 1994-11-03 | 1997-06-17 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US6027888A (en) | 1996-04-05 | 2000-02-22 | Board Of Regents, The University Of Texas System | Methods for producing soluble, biologically-active disulfide-bond containing eukaryotic proteins in bacterial cells |
| AU751659B2 (en) | 1997-05-02 | 2002-08-22 | Genentech Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US6083715A (en) | 1997-06-09 | 2000-07-04 | Board Of Regents, The University Of Texas System | Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| DK1783222T3 (da) | 1998-10-23 | 2012-07-09 | Kirin Amgen Inc | Dimere trombopoietiske peptidomimetika, der binder til MPL-receptor og har trombopoietisk aktivitet |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| SI2857516T1 (sl) | 2000-04-11 | 2017-09-29 | Genentech, Inc. | Multivalentna protitelesa in njihove uporabe |
| US6979556B2 (en) | 2000-12-14 | 2005-12-27 | Genentech, Inc. | Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes |
| US8372954B2 (en) | 2000-12-22 | 2013-02-12 | National Research Council Of Canada | Phage display libraries of human VH fragments |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| CN100448891C (zh) | 2001-05-11 | 2009-01-07 | 安姆根有限公司 | 与tall-1结合的肽和相关分子 |
| US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
| US7332474B2 (en) | 2001-10-11 | 2008-02-19 | Amgen Inc. | Peptides and related compounds having thrombopoietic activity |
| US7205275B2 (en) | 2001-10-11 | 2007-04-17 | Amgen Inc. | Methods of treatment using specific binding agents of human angiopoietin-2 |
| JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
| US7317091B2 (en) * | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
| US6919426B2 (en) | 2002-09-19 | 2005-07-19 | Amgen Inc. | Peptides and related molecules that modulate nerve growth factor activity |
| KR100980065B1 (ko) * | 2002-09-27 | 2010-09-03 | 젠코어 인코포레이티드 | 최적화된 Ｆｃ 변이체 및 그의 제조 방법 |
| US20090010920A1 (en) * | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| US8084582B2 (en) * | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| MXPA05012723A (es) | 2003-05-30 | 2006-02-08 | Genentech Inc | Tratamiento con anticuerpos anti-vgf. |
| DK1639011T3 (da) | 2003-06-30 | 2009-02-16 | Domantis Ltd | Pegylerede enkelt-domæne antistoffer (dAb) |
| HN2004000285A (es) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
| US7472724B2 (en) | 2003-08-18 | 2009-01-06 | Electrolock, Inc. | Method and apparatus for creating, using, and dispensing tubes |
| SG149815A1 (en) | 2003-11-06 | 2009-02-27 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
| ATE554107T1 (de) | 2003-12-19 | 2012-05-15 | Genentech Inc | Als therapeutika geeignete monovalente antikörperfragmente |
| EP3718564B1 (en) | 2003-12-23 | 2023-10-11 | Genentech, Inc. | Novel anti-il 13 antibodies and uses thereof |
| US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
| US20070048785A1 (en) | 2004-06-09 | 2007-03-01 | Lin Laura L | Anti-IL-13 antibodies and complexes |
| AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| EP2940043A1 (en) * | 2004-07-15 | 2015-11-04 | Xencor, Inc. | Optimized fc variants |
| AR050044A1 (es) | 2004-08-03 | 2006-09-20 | Novartis Ag | Anticuerpo especifico de il-4 |
| JP2008511337A (ja) | 2004-09-02 | 2008-04-17 | ジェネンテック・インコーポレーテッド | ヘテロ多量体分子 |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| PT1951759E (pt) | 2005-11-12 | 2010-04-01 | Lilly Co Eli | Anticorpos anti-egfr |
| EP2035456A1 (en) | 2006-06-22 | 2009-03-18 | Novo Nordisk A/S | Production of bispecific antibodies |
| EP2087111A2 (en) * | 2007-03-19 | 2009-08-12 | Medimmune Limited | Polypeptide variants |
| WO2009089004A1 (en) | 2008-01-07 | 2009-07-16 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| ES2537100T3 (es) * | 2009-04-07 | 2015-06-02 | Roche Glycart Ag | Anticuerpos biespecíficos trivalentes |
-
2012
- 2012-02-03 MX MX2013008920A patent/MX355255B/es active IP Right Grant
- 2012-02-03 WO PCT/US2012/023749 patent/WO2012106587A1/en not_active Ceased
- 2012-02-03 RU RU2018108836A patent/RU2018108836A/ru unknown
- 2012-02-03 EP EP12704198.6A patent/EP2670776B1/en active Active
- 2012-02-03 CA CA2825064A patent/CA2825064C/en active Active
- 2012-02-03 KR KR1020137023274A patent/KR101913448B1/ko not_active Expired - Fee Related
- 2012-02-03 JP JP2013552669A patent/JP6161540B2/ja active Active
- 2012-02-03 RU RU2013140685/10A patent/RU2013140685A/ru not_active Application Discontinuation
- 2012-02-03 AR ARP120100365A patent/AR085138A1/es active IP Right Grant
- 2012-02-03 CN CN201280016878.3A patent/CN103649117B/zh active Active
- 2012-02-03 BR BR112013019499-5A patent/BR112013019499B1/pt not_active IP Right Cessation
-
2016
- 2016-07-04 JP JP2016132391A patent/JP2017006128A/ja active Pending
-
2022
- 2022-10-31 AR ARP220102969A patent/AR127516A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2670776A1 (en) | 2013-12-11 |
| AR085138A1 (es) | 2013-09-11 |
| AR127516A2 (es) | 2024-01-31 |
| JP6161540B2 (ja) | 2017-07-12 |
| BR112013019499B1 (pt) | 2023-01-10 |
| JP2014506790A (ja) | 2014-03-20 |
| CN103649117B (zh) | 2016-09-14 |
| WO2012106587A1 (en) | 2012-08-09 |
| CN103649117A (zh) | 2014-03-19 |
| RU2018108836A3 (enExample) | 2019-03-14 |
| BR112013019499A2 (pt) | 2020-03-10 |
| CA2825064A1 (en) | 2012-08-09 |
| KR20140043722A (ko) | 2014-04-10 |
| HK1196020A1 (zh) | 2014-11-28 |
| EP2670776B1 (en) | 2018-11-21 |
| CA2825064C (en) | 2022-08-30 |
| RU2018108836A (ru) | 2019-03-14 |
| JP2017006128A (ja) | 2017-01-12 |
| KR101913448B1 (ko) | 2018-10-30 |
| MX355255B (es) | 2018-04-11 |
| MX2013008920A (es) | 2013-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013140685A (ru) | ВАРИАНТЫ Fc, СПОСОБЫ ИХ ПОЛУЧЕНИЯ | |
| JP2014506790A5 (enExample) | ||
| CA3129193C (en) | Anti-vegf protein compositions and methods for producing the same | |
| JP2017512063A5 (enExample) | ||
| JP2017509335A5 (enExample) | ||
| JP7138046B2 (ja) | 二特異性抗体基幹 | |
| RU2012122173A (ru) | Варианты альбумина | |
| NZ701825A (en) | Heterodimeric antibody fc-containing proteins and methods for production thereof | |
| IL273918B2 (en) | Trispecific proteins and methods of use | |
| FI3998285T3 (fi) | Cd38:aan ja pd-l1:een sitoutuvia molekyylejä | |
| IL278014B2 (en) | Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use | |
| RU2010122053A (ru) | Иммуносупрессорные полипептиды и нуклеиновые кислоты | |
| RU2012122402A (ru) | Содержащие фактор фон виллебранда (vwf) препараты и способы, наборы и применения, связанные с ними | |
| AR080942A1 (es) | Produccion de proteinas heteromultimericas | |
| RU2013143303A (ru) | FcγRIIb-СПЕЦИФИЧНОЕ Fc-АНТИТЕЛО | |
| JPWO2020072821A5 (enExample) | ||
| WO2020226502A3 (en) | Variant domains for multimerizing proteins and separation thereof | |
| CA2508925A1 (en) | Product quality enhancement in mammalian cell culture processes for protein production | |
| JP2018514209A5 (enExample) | ||
| RU2016140244A (ru) | Способы и композиции для секреции гетерологичных полипептидов | |
| JP2020509755A5 (enExample) | ||
| JPWO2012017925A1 (ja) | 物質の製造方法 | |
| RU2014144881A (ru) | Способ экспрессии полипептидов с применением модифицированных нуклеиновых кислот | |
| RU2016142324A (ru) | Получение гетеромультимерных белков с использованием клеток млекопитающих | |
| CN112552414A (zh) | 一种lilrb4和b7-h3双靶向的嵌合抗原受体及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20170530 |
|
| FZ9A | Application not withdrawn (correction of the notice of withdrawal) |
Effective date: 20170804 |